Do analysts recommend ITRM or TRAW?

Traws Pharma has a consensus target price of $1.00, indicating a potential upside of 170.78%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than Iterum Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Traws Pharma 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Is ITRM or TRAW more profitable?

Iterum Therapeutics' return on equity of 0.00% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Traws Pharma N/A -23,868.92% -165.52%

Do analysts recommend ITRM or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend LIAN or ITRM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is LIAN or ITRM more profitable?

Iterum Therapeutics' return on equity of 0.00% beat LianBio's return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Iterum Therapeutics N/A N/A -65.54%

Do analysts recommend ITRM or PCSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ITRM or PCSA more profitable?

Iterum Therapeutics' return on equity of 0.00% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Heatwurx N/A -394.25% -244.46%

Do analysts rate GELS or ITRM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has better valuation & earnings, GELS or ITRM?

Gelteq has higher earnings, but lower revenue than Iterum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 43.42 -$4.30M N/A N/A Iterum Therapeutics $390K 4.10 -$24.77M -$0.75 N/A

Is GELS or ITRM more profitable?

Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A Iterum Therapeutics N/A N/A -65.54%

Iterum Therapeutics (ITRM) Competitors

$0.03 0.00 (0.00%)

As of 10/16/2026

Compare

ITRM vs. TRAW, SNOA, LIAN, PCSA, and GELS

Should you buy Iterum Therapeutics stock or one of its competitors? Iterum Therapeutics's main competitors and comparable companies include Traws Pharma (TRAW), Sonoma Pharmaceuticals (SNOA), LianBio (LIAN), Heatwurx (PCSA), and Gelteq (GELS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Iterum Therapeutics compare to Traws Pharma?

Iterum Therapeutics (NASDAQ:ITRM) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

Iterum Therapeutics' return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Traws Pharma	N/A	-23,868.92%	-165.52%

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Traws Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Traws Pharma has higher revenue and earnings than Iterum Therapeutics. Traws Pharma is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Traws Pharma	$2.79M	2.03	$9.17M	-$1.74	N/A

Iterum Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Traws Pharma has a consensus target price of $1.00, indicating a potential upside of 170.78%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than Iterum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Traws Pharma's average media sentiment score of 1.82 beat Iterum Therapeutics' score of 0.00 indicating that Traws Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Traws Pharma	Very Positive

Summary

Iterum Therapeutics and Traws Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Iterum Therapeutics compare to Sonoma Pharmaceuticals?

Iterum Therapeutics (NASDAQ:ITRM) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Sonoma Pharmaceuticals has higher revenue and earnings than Iterum Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Sonoma Pharmaceuticals	$19.53M	0.27	-$3.17M	-$1.22	N/A

In the previous week, Sonoma Pharmaceuticals' average media sentiment score of 1.82 beat Iterum Therapeutics' score of 0.00 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Sonoma Pharmaceuticals	Very Positive

Iterum Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Iterum Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Iterum Therapeutics' return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%

9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by company insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Iterum Therapeutics beats Sonoma Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Iterum Therapeutics compare to LianBio?

LianBio (NASDAQ:LIAN) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

In the previous week, LianBio's average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
Iterum Therapeutics	Neutral

Iterum Therapeutics' return on equity of 0.00% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Iterum Therapeutics	N/A	N/A	-65.54%

Iterum Therapeutics has higher revenue and earnings than LianBio. LianBio is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

74.8% of LianBio shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 7.6% of LianBio shares are held by company insiders. Comparatively, 2.0% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the broader market.

Summary

Iterum Therapeutics beats LianBio on 7 of the 10 factors compared between the two stocks.

How does Iterum Therapeutics compare to Heatwurx?

Iterum Therapeutics (NASDAQ:ITRM) and Heatwurx (NASDAQ:PCSA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 91.9% of Heatwurx shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Heatwurx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Iterum Therapeutics has a beta of 2.96, indicating that its share price is 196% more volatile than the broader market. Comparatively, Heatwurx has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

Iterum Therapeutics' return on equity of 0.00% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Heatwurx	N/A	-394.25%	-244.46%

In the previous week, Heatwurx had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 1 mentions for Heatwurx and 0 mentions for Iterum Therapeutics. Heatwurx's average media sentiment score of 1.03 beat Iterum Therapeutics' score of 0.00 indicating that Heatwurx is being referred to more favorably in the news media.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Heatwurx	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Heatwurx has lower revenue, but higher earnings than Iterum Therapeutics. Heatwurx is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A

Summary

Iterum Therapeutics beats Heatwurx on 7 of the 12 factors compared between the two stocks.

How does Iterum Therapeutics compare to Gelteq?

Gelteq (NASDAQ:GELS) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Gelteq has a beta of -0.41, meaning that its share price is 141% less volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, meaning that its share price is 196% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Gelteq had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 1 mentions for Gelteq and 0 mentions for Iterum Therapeutics. Gelteq's average media sentiment score of 0.60 beat Iterum Therapeutics' score of 0.00 indicating that Gelteq is being referred to more favorably in the media.

Company	Overall Sentiment
Gelteq	Positive
Iterum Therapeutics	Neutral

Gelteq has higher earnings, but lower revenue than Iterum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	43.42	-$4.30M	N/A	N/A
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

9.2% of Iterum Therapeutics shares are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Iterum Therapeutics	N/A	N/A	-65.54%

Summary

Gelteq and Iterum Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

Get Iterum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ITRM vs. The Competition

Export

Metric	Iterum Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.60M	$12.78B	$7.44B	$12.68B
Dividend Yield	N/A	2.60%	2.50%	32.09%
P/E Ratio	-0.04	620.71	194.37	19.23
Price / Sales	4.10	745.29	570.76	76.91
Price / Cash	N/A	80.22	74.88	50.51
Price / Book	-0.20	9.21	10.31	5.85
Net Income	-$24.77M	$2.85B	$3.51B	$381.63M
7 Day Performance	N/A	-5.25%	-5.47%	-5.04%
1 Month Performance	N/A	-9.18%	-9.66%	-7.99%
1 Year Performance	N/A	-6.07%	0.73%	-5.68%

Iterum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ITRM Iterum Therapeutics	N/A	$0.03 flat	N/A	N/A	$1.60M	$390K	N/A	10
TRAW Traws Pharma	1.697 of 5 stars	$0.41 -1.4%	$1.00 +143.8%	-86.2%	$6.39M	$2.79M	N/A	7	News Coverage Positive News
SNOA Sonoma Pharmaceuticals	0.3696 of 5 stars	$1.18 -4.1%	N/A	-72.5%	$5.89M	$19.53M	N/A	260	Gap Up
LIAN LianBio	N/A	$0.05 flat	N/A	-15.0%	$5.51M	N/A	N/A	110
PCSA Heatwurx	1.1516 of 5 stars	$1.77 -6.8%	N/A	-81.2%	$5.32M	N/A	N/A	12	Positive News Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ITRM) was last updated on 10/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iterum Therapeutics (ITRM) Competitors

ITRM vs. TRAW, SNOA, LIAN, PCSA, and GELS

How does Iterum Therapeutics compare to Traws Pharma?

Summary

How does Iterum Therapeutics compare to Sonoma Pharmaceuticals?

Summary

How does Iterum Therapeutics compare to LianBio?

Summary

How does Iterum Therapeutics compare to Heatwurx?

Summary

How does Iterum Therapeutics compare to Gelteq?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITRM vs. The Competition

Iterum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iterum Therapeutics (ITRM) Competitors

ITRM vs. TRAW, SNOA, LIAN, PCSA, and GELS

How does Iterum Therapeutics compare to Traws Pharma?

Is ITRM or TRAW more profitable?

Do insiders and institutionals believe in ITRM or TRAW?

Which has stronger earnings and valuation, ITRM or TRAW?

Which has more risk & volatility, ITRM or TRAW?

Do analysts recommend ITRM or TRAW?

Does the media favor ITRM or TRAW?

Summary

How does Iterum Therapeutics compare to Sonoma Pharmaceuticals?

Which has better earnings and valuation, ITRM or SNOA?

Does the media refer more to ITRM or SNOA?

Which has more risk and volatility, ITRM or SNOA?

Do analysts recommend ITRM or SNOA?

Is ITRM or SNOA more profitable?

Do insiders & institutionals hold more shares of ITRM or SNOA?

Summary

How does Iterum Therapeutics compare to LianBio?

Does the media prefer LIAN or ITRM?

Is LIAN or ITRM more profitable?

Which has stronger earnings & valuation, LIAN or ITRM?

Do institutionals and insiders hold more shares of LIAN or ITRM?

Do analysts recommend LIAN or ITRM?

Which has more volatility and risk, LIAN or ITRM?

Summary

How does Iterum Therapeutics compare to Heatwurx?

Do institutionals & insiders believe in ITRM or PCSA?

Which has more volatility & risk, ITRM or PCSA?

Is ITRM or PCSA more profitable?

Does the media refer more to ITRM or PCSA?

Do analysts recommend ITRM or PCSA?

Which has preferable valuation & earnings, ITRM or PCSA?

Summary

How does Iterum Therapeutics compare to Gelteq?

Which has more risk & volatility, GELS or ITRM?

Do analysts rate GELS or ITRM?

Does the media prefer GELS or ITRM?

Which has better valuation & earnings, GELS or ITRM?

Do insiders & institutionals have more ownership in GELS or ITRM?

Is GELS or ITRM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITRM vs. The Competition

Iterum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools